Product image of Methotrexaat Cf (Methotrexate) supplied by GNH India

Methotrexaat Cf

Active Ingredient:
Methotrexate
Origin:
EU

Methotrexaat Cf (Methotrexate)

Methotrexate, the active ingredient in Methotrexaat Cf, is an antimetabolite (folate antagonist) presented as an injectable solution for intramuscular, intravenous, or subcutaneous administration. It is used to manage autoimmune disorders and certain malignancies in adult and pediatric patients.

GNH India supplies Methotrexaat Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution. GNH India’s global network ensures reliable delivery to clinical sites across Europe, Asia, Africa and the Americas.

Manufacturer / TM Owner

Centrafarm B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methotrexate is employed in several autoimmune and oncologic disease pathways to modify disease activity and improve outcomes.

  • Rheumatoid arthritis: reduces joint inflammation and slows structural damage.
  • Psoriasis: decreases skin cell proliferation, leading to clearance of plaques.
  • Acute lymphoblastic leukemia: interferes with malignant cell replication, contributing to remission.
  • Non‑Hodgkin lymphoma: impairs tumor growth, used as part of combination chemotherapy.
  • Breast cancer: administered in high‑dose protocols to enhance cytotoxic effect on tumor cells.

How It Works

  • Methotrexate inhibits the enzyme dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate. This reduction limits the cellular pool of tetrahydrofolate required for synthesis of purine nucleotides and thymidylate, thereby impairing DNA, RNA and protein synthesis. The resulting antiproliferative effect is most pronounced in rapidly dividing immune cells and malignant cells, accounting for its immunosuppressive and antineoplastic actions.

Side Effects

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea and vomiting
  • Fatigue
  • Mouth sores (stomatitis)
  • Low white blood cell count (leukopenia)
  • Elevated liver enzymes

Serious or Rare Side Effects

  • Severe bone marrow suppression (pancytopenia)
  • Pulmonary toxicity (interstitial pneumonitis)
  • Hepatic fibrosis or cirrhosis
  • Renal impairment
  • Severe cutaneous reactions (Stevens‑Johnson syndrome)

Precautions & Warnings

Before initiating therapy with Methotrexaat Cf, several precautionary measures should be observed to minimize risk.

  • Baseline testing: obtain complete blood count, liver and renal function tests prior to treatment.
  • Monitoring: schedule regular laboratory assessments to detect hematologic or hepatic toxicity.
  • Concomitant folic acid: supplement as advised to reduce mucosal and hematologic side effects.
  • Pregnancy and lactation: avoid use in pregnant or breastfeeding individuals unless benefits outweigh risks.
  • Drug interactions: review patient medication list for agents that may increase toxicity.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Methotrexate interacts with several medicines that can alter its efficacy or increase toxicity.

Major Interactions (Avoid)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce renal clearance and raise methotrexate levels.
  • Proton pump inhibitors (e.g., omeprazole): can impair renal elimination, increasing toxicity risk.
  • Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression.

Moderate Interactions (Monitor Closely)

  • Azathioprine or other immunosuppressants: additive myelosuppression may occur.
  • Live vaccines: risk of severe infection due to immunosuppression.
  • Vitamin B12 or folate supplements: may diminish therapeutic effect if not properly timed.

Frequently Asked Questions

Methotrexaat Cf, containing methotrexate, is indicated for several autoimmune and oncologic conditions. It is used to treat rheumatoid arthritis and severe psoriasis, as well as certain cancers such as acute lymphoblastic leukemia, non‑Hodgkin lymphoma and breast cancer, often as part of combination therapy.

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This limits the synthesis of nucleotides needed for DNA, RNA and protein production, thereby reducing the proliferation of rapidly dividing immune cells and cancer cells.

The dose of Methotrexaat Cf is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal function and other clinical factors. No fixed regimen is provided here; the prescriber sets the appropriate dosage.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal harm. It is also generally avoided during breastfeeding unless the potential benefit justifies the risk. Women of child‑bearing potential should use effective contraception while on therapy.

To request Methotrexaat Cf, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Methotrexaat Cf is a folate antagonist, whereas other antimetabolites such as 5‑fluorouracil target thymidylate synthase. Methotrexate’s broad immunosuppressive and antineoplastic activity makes it suitable for both autoimmune diseases and a range of cancers, while some alternatives are more disease‑specific.

Methotrexaat Cf should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product to maintain stability.

Methotrexaat Cf is supplied as an injectable solution and can be given by intramuscular, intravenous or subcutaneous injection. The route, volume and rate of administration are determined by the treating physician according to the clinical indication.

Serious adverse events include severe bone‑marrow suppression (pancytopenia), hepatic fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, and renal impairment. Patients should be monitored regularly for blood counts, liver and kidney function, and any respiratory symptoms.

Methotrexaat Cf is contraindicated in patients with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active infections, and in pregnant or breastfeeding women unless the benefits outweigh the risks. Caution is also advised for individuals with pre‑existing blood dyscrasias.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methotrexate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT